BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Beckman Coulter and Illumina Streamline Oncology Research with New Automated Genomic Profiling Solution

NextEdge Admin

09 Aug 2024

1 min 47 sec

Beckman Coulter Life Sciences and Illumina have introduced a new automated solution for oncology research, integrating the Illumina TruSight™ Oncology 500 DNA/RNA assay with the Biomek NGeniuS System. This collaboration streamlines comprehensive genomic profiling of tumor samples, supporting both DNA and RNA inputs to detect key cancer biomarkers like SNVs, gene amplifications, and fusions. The system enables complete library preparation in under three days, significantly reducing manual work and enhancing precision.

The Biomek NGeniuS System can process four to 24 libraries in a single batch, accommodating both high and low-quality FFPE samples. The assay is designed to reduce plastic use and lower consumable costs, promoting sustainability in cutting-edge research.

Ewan Grant of Beckman Coulter highlighted the importance of delivering faster, more reliable data, while Illumina’s Mike Kreitzinger emphasized the system's ability to reduce hands-on time and improve the user experience. Launched in June 2022, the Biomek NGeniuS System is optimized for low-medium throughput NGS library preparation, minimizing user errors and manual interventions in the process. This collaboration continues the companies' efforts to advance automated solutions in clinical oncology research.